If you have chronic Hepatitis B, there is a direct, specific question you should bring to your next doctor's appointment: Have I ever been tested for Hepatitis Delta Virus?
For years, the honest clinical answer to why that test was often skipped was straightforward: there was nothing to do with a positive result. That has changed. On May 22, 2026, the FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) as the first-ever treatment for chronic Hepatitis Delta Virus (HDV) infection in the United States — and that single regulatory decision has shifted the clinical calculus for testing an estimated 80,000 Americans who may be living with this dangerous, undiagnosed co-infection right now.
Why This Matters
Hepatitis Delta Virus cannot infect a person on its own — it is what virologists call a "satellite virus," capable of infecting and replicating only in people who already have chronic Hepatitis B, because HDV requires the Hepatitis B surface antigen to enter and persist in liver cells. According to the Hepatitis B Foundation, an estimated 4 percent of Americans living with chronic Hepatitis B also have HDV — approximately 80,000 people nationally.
The consequence of that co-infection is severe and disproportionate to its rarity. HDV dramatically accelerates the progression of liver disease compared to Hepatitis B alone — patients with HDV co-infection progress to cirrhosis roughly three times faster, and their risk of liver cancer is substantially elevated. The World Health Organization describes HDV as the most severe form of chronic viral hepatitis, specifically because of this accelerated disease course.
What We Know So Far
Bulevirtide was approved under the FDA's Accelerated Approval pathway, having previously received Priority Review, Breakthrough Therapy Designation, and Orphan-Drug Designation — a combination of regulatory designations that reflects both the seriousness of the disease and the strength of the clinical evidence supporting the drug.
The approval covers adults with chronic HDV infection who do not have cirrhosis or who have compensated (stable, non-decompensated) cirrhosis. Wendy Carter, DO, Acting Director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research, said in the agency's approval announcement: "Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available."
The approval was supported by data from the Phase 3 MYR301 trial, which showed steadily improving virologic response with extended treatment: 20 percent of patients in the immediate-treatment arm achieved undetectable HDV RNA at week 48, rising to 36 percent at week 96 and 50 percent at week 144. By comparison, no participants in the delayed-treatment comparison group achieved undetectable HDV RNA at week 48, providing clear evidence of the drug's direct treatment effect.
Why Testing Was Historically Deprioritized — and Why That Logic No Longer Applies
For years, the clinical argument against universal HDV testing in chronic Hepatitis B patients was a pragmatic one: in the absence of any approved treatment, identifying a positive HDV result offered limited actionable benefit beyond informing more intensive monitoring. Clinicians, particularly in resource-constrained settings, often deprioritize HDV testing in favor of focusing resources on Hepatitis B management itself.
That logic depended entirely on the absence of treatment. With bulevirtide now FDA-approved, a positive HDV test result leads directly to a meaningful treatment option for the first time in U.S. clinical history. The case for universal HDV antibody testing in all chronic Hepatitis B patients is now substantially stronger and reflects the emerging standard among hepatology and infectious disease specialists.
Who Should Specifically Ask About Testing
Infectious disease and hepatology specialists particularly recommend HDV antibody testing for chronic Hepatitis B patients who:
- Were born in or have immigrated from regions with higher HDV prevalence, including Mongolia, Central Asia (Kazakhstan, Tajikistan, Uzbekistan), Eastern Europe, Romania, West Africa, the Amazon basin of South America, and parts of the Middle East
- Have a history of injection drug use
- Have experienced unexplained rapid progression of liver disease or persistently elevated liver enzymes despite Hepatitis B treatment
- Have a sexual partner with confirmed HDV infection
- Have never previously been tested for HDV despite a long-standing chronic Hepatitis B diagnosis
Testing itself is straightforward: it begins with an anti-HDV antibody blood test. A positive antibody result is followed by quantitative HDV RNA testing to confirm active, ongoing infection requiring treatment consideration.
What Doctors and Experts Say
Chari A. Cohen, DrPH, MPH, president of the Hepatitis B Foundation, called the approval a "game changer": "Until now, there was very little that we could do to prevent cirrhosis and liver cancer for people living with hepatitis delta in the U.S. All of us at the Hepatitis B Foundation are optimistic that the FDA's approval of Hepcludex will be a game changer, leading to improved HDV screening, diagnosis, care and treatment across the U.S."
The drug's prescribing information includes an important boxed warning: discontinuation of bulevirtide may result in severe acute exacerbations of both HDV and Hepatitis B infection, given the obligate co-infection biology of the two viruses. Patients who begin treatment require ongoing monitoring, including careful management if treatment is ever discontinued.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Drug: Bulevirtide-gmod (Hepcludex), 8.5 mg daily subcutaneous injection
- FDA approval: May 22, 2026, Accelerated Approval pathway
- Indicated for: Adults with chronic HDV infection, without cirrhosis or with compensated cirrhosis
- Trial evidence: Phase 3 MYR301 — undetectable HDV RNA in 20% (week 48), 36% (week 96), 50% (week 144) of treated patients, versus 0% in the delayed-treatment comparison group at week 48
- Durability: 90% of patients who achieved undetectable HDV RNA at week 96 remained undetectable nearly two years post-treatment, per final MYR301 data
- Important limitation: Bulevirtide does not eliminate underlying Hepatitis B infection — patients may still require separate, ongoing HBV monitoring or antiviral therapy
- Boxed warning: Discontinuing treatment may cause severe flares of both HDV and HBV infection
Who Faces the Greatest Risk From Undiagnosed HDV?
- Chronic Hepatitis B patients who have never been tested for HDV co-infection
- Patients experiencing unexplained, faster-than-expected liver disease progression
- Immigrants from high-HDV-prevalence regions who may not have been routinely screened in prior care settings
- People with both chronic Hepatitis B and a history of injection drug use, given the elevated co-infection risk in this population
What You Can Do Now
- If you have chronic Hepatitis B and have never been tested for Hepatitis Delta Virus, ask your hepatologist, gastroenterologist, or infectious disease specialist about an anti-HDV antibody test at your next visit, or call to schedule a dedicated appointment for this purpose now.
- If you previously tested positive for HDV antibodies but were told there was no treatment available at the time, follow up with your physician about whether HDV RNA testing and bulevirtide treatment are now appropriate for you.
- If you are diagnosed with chronic HDV, discuss with your liver specialist whether you meet the indication criteria for bulevirtide, and what ongoing monitoring will be required during treatment.
- Do not stop any existing Hepatitis B antiviral therapy without your physician's guidance, given the boxed warning about exacerbation risk upon treatment discontinuation.
Cost and Access: What Patients Should Know
HDV antibody testing and confirmatory RNA testing are generally covered by insurance plans when ordered by a physician for a patient with confirmed chronic Hepatitis B. Bulevirtide (Hepcludex) is a specialty medication; Gilead Sciences offers a patient support program for both insured and uninsured eligible patients. Contact your physician's office or Gilead directly for current patient assistance program details.
What Happens Next
As an accelerated approval, bulevirtide's continued availability is contingent on confirmatory post-marketing study data. Gilead Sciences continues additional research into longer-term outcomes and potential combination regimens. MedicalDaily will report on confirmatory trial results and any updated hepatology society guidelines incorporating universal HDV testing recommendations.
The Bottom Line
For the first time in U.S. medical history, there is an FDA-approved treatment for Hepatitis Delta Virus — and that single fact should change the testing conversation for every one of the estimated 80,000 Americans living with undiagnosed chronic Hepatitis B and HDV co-infection. If you have chronic Hepatitis B and have never been tested for HDV, the single most useful thing you can do right now is ask your doctor for the test.
